Kallikrein 13 antibody (AA 262-277)

Catalog No. ABIN289487

The Rabbit Polyclonal anti-Kallikrein 13 antibody has been validated for WB. It is suitable to detect Kallikrein 13 in samples from Human.

Quick Overview for Kallikrein 13 antibody (AA 262-277) (ABIN289487)

Target: Kallikrein 13 (KLK13) (Kallikrein-Related Peptidase 13 (KLK13))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Kallikrein 13 antibody is un-conjugated

Application: Western Blotting (WB)

Product Details anti-Kallikrein 13 Antibody

Binding Specificity: AA 262-277

Purification: Affinity chromatography purified

Immunogen: KLK-L4 antibody was raised in rabbit using AA 262-277 [IRKYETQQQKWLKGPQ] of the human KLK-L4 protein as the immunogen.

Isotype: IgG

Application Details

Application Notes: WB: 1:500-1:1,000
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: Lot specific

Buffer: Affinity purified IgG supplied in PBS with 0.02 % NaN3.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handling Advice: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Storage: 4 °C/-20 °C

Storage Comment: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Target Details for Kallikrein 13

Target: Kallikrein 13 (KLK13) (Kallikrein-Related Peptidase 13 (KLK13))

Alternative Name: KLK-L4

Background: Kallikreins are a subgroup of serine proteases and are implicated in carcinogenesis. The novel KLK gene, KLK-L4, is expressed in a variety of tissues including prostate, salivary gland, breast, and testis. Its expression is regulated by steroid hormones in breast cancer cell lines may be involved in the pathogenesis and/or progression of breast cancer.

Pathways: Complement System